News

Zhitong
2025.10.30 13:49

In early trading on Thursday, shares of Eli Lilly rose 1.9% after the company reported that its third-quarter performance exceeded expectations due to a surge in sales of Zepbound and Mounjaro, and it raised its revenue and earnings per share guidance for 2025

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.